

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Akesobio

Akeso, Inc.

康方生物科技（開曼）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9926)

**DIS-APPLICATION OF RULES 18A.09
TO 18A.11 OF THE LISTING RULES
AND
REMOVAL OF STOCK MARKER**

Akeso, Inc. (the “**Company**”) is pleased to announce that following an application to The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 18A.12 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”), the Stock Exchange has granted approval for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules (the “**Relevant Rules**”) to the Company.

As a result of the dis-application of the Relevant Rules, the “B” marker will no longer be affixed to the Company’s English and Chinese stock short name from March 28, 2023.

REASONS FOR THE DIS-APPLICATION OF THE RELEVANT RULES

The Company is a biotechnology company which listed its ordinary shares (the “**Shares**”) on the Main Board of the Stock Exchange on April 24, 2020 pursuant to Chapter 18A of the Listing Rules.

The Company now satisfies the market capitalization/revenue test under Rule 8.05(3) of the Listing Rules. In particular, the Company has a trading record of at least three financial years, management continuity for at least the three preceding financial years and ownership continuity and control for at least the most recent audited financial year. The Company’s market capitalization as of March 20, 2023 was over HK\$36 billion, which is in excess of HK\$4 billion as required under Rule 8.05(3) of the Listing Rules. As stated in the annual results announcement of the Company for the year ended December 31, 2022 dated March 15, 2023, the Company’s total revenue for the year ended December 31, 2022, being the most recent audited financial year, was approximately RMB837.7 million (equivalent to approximately HK\$957.1 million), which is in excess of HK\$500 million as required under

Rule 8.05(3) of the Listing Rules. Accordingly, the Company qualifies for listing under Rule 8.05(3) of the Listing Rules and the Stock Exchange has therefore granted its approval for the application for dis-application of the Relevant Rules to the Company.

EFFECTS OF THE DIS-APPLICATION OF THE RELEVANT RULES

Following the dis-application of the Relevant Rules, the “B” marker will cease to be affixed to the Company’s English and Chinese stock short name. There will be otherwise no effect on the existing share certificates in respect of the Company’s Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates for holders of Shares. No other changes will be made to the English or Chinese stock short name of the Company, the existing share certificates, the board lot size, the trading currency of the Shares and the share registrar and transfer offices of the Company following the dis-application of the Relevant Rules.

For the purpose of this announcement and for illustrative purpose only, conversions of RMB to HK\$ are based on the exchange rate of RMB0.87523 = HK\$1.00. No representation is made that any amounts in HK\$ or RMB can be or could have been converted at the relevant dates at the above rate or at any other rates or at all.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairman and executive director

Hong Kong, March 23, 2023

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive directors, Dr. ZHOU Yi and Mr. XIE Ronggang as non-executive directors, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.